Revenue ₹4,517 Cr (+10% YoY)
0 met · 0 close · 20 missed across 21 tracked promises
View all executive profiles for Biocon LimitedBiocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, dri...
0% promises delivered
Based on 21 tracked promises across 12 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
15 May 2026
Revenue ₹4,517 Cr (+10% YoY)
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in bio...
bullish
high
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
10 Feb 2026
Revenue ₹4,173 Cr (+9% YoY)
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last...
bullish
high
4 missed
Read full analysis →
Q2 FY26
31 Oct 2025
Revenue ₹4,296 Cr (+20% YoY)
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generi...
bullish
high
2 missed, 1 delayed
Read full analysis →
Q1 FY26
15 Jul 2025
Revenue ₹3,942 Cr (+15% YoY)
Biocon Group delivered a strong Q1 FY26 with consolidated operating revenue of INR 3,942 crore, up 15% YoY on a like-for-like basis.
bullish
high
2 missed
Read full analysis →
Q4 FY25
15 May 2025
Revenue ₹4,417 Cr (+15% YoY)
Biocon delivered a strong Q4 FY25 with consolidated revenue of INR 4,417 crore, up 15% YoY on a like-for-like basis, driven by generics (+46% YoY) and biosimilars (+9%...
bullish
high
3 missed
Read full analysis →
Q3 FY25
31 Jan 2025
Revenue ₹3,821 Cr (+10% YoY)
Biocon's Q3 FY25 results were in line with expectations, with consolidated revenue from operations of INR 3,821 crore, up 10% YoY on a like-for-like basis.
bullish
high
3 missed
Read full analysis →
Q2 FY25
30 Oct 2024
Revenue ₹3,590 Cr (+8% YoY)
Biocon's Q2 FY25 consolidated revenue from operations grew 8% YoY to ₹3,590 crore, driven by biosimilars (up 19% like-for-like) but offset by generics decline (-8%) an...
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q1 FY25
09 Aug 2024
Revenue ₹3,433 Cr (0% YoY)
Biocon's Q1 FY25 revenue from operations was flat YoY at INR 3,433 crore, with adjusted EBITDA of INR 698 crore (20% margin) and adjusted PAT of INR 19 crore.
neutral
medium
1 missed
Read full analysis →
Q4 FY24
15 May 2024
Revenue ₹3,917 Cr (+4% YoY)
Biocon's Q4 FY24 group revenue from operations grew 4% YoY to INR 3,917 crore, with core EBITDA margin of 30%.
neutral
medium
2 missed
Read full analysis →
Q3 FY24
02 Feb 2024
Revenue ₹3,954 Cr (+34% YoY)
Biocon's Q3 FY24 consolidated revenue from operations grew 34% YoY to INR 3,954 crore, driven by a 65% surge in biosimilars revenue, partially offset by a 7% decline i...
neutral
medium
3 missed
Read full analysis →
Q2 FY24
10 Nov 2023
Revenue ₹3,462 Cr (+49% YoY)
Biocon's Q2 FY24 consolidated revenue from operations grew 49% YoY to INR 3,462 crore, driven by biosimilars revenue nearly doubling post-Viatris acquisition.
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q1 FY24
09 Aug 2023
Revenue ₹3,423 Cr (+59% YoY)
Biocon Group delivered a strong revenue-led Q1 FY24, with consolidated revenue up 59% YoY to INR 3,516 crore, driven by the Viatris biosimilars acquisition and robust...
bullish
medium
Scorecard starts after historical backfill
Read full analysis →